nach oben

Erschienen in:

11.01.2023 | Original Research

Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males

verfasst von: Jiangfan Li, Yan Tan, Kexin Li, Ai-Min Hui, Zhuli Wu, Pu Han, Zhen Wei, Jingjun Qiu, Lei Diao, Xuhong Wang

Erschienen in: Advances in Therapy | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

FCN-159 is a novel, oral, potent, selective MEK1/2 inhibitor in clinical development for the treatment of NRAS-mutant advanced melanoma and neurofibromatosis type 1. We investigated the effect of food on the pharmacokinetics (PK), safety, and tolerability of FCN-159.

Methods

In this single-center, open-label, phase 1 study with a three-period, three-sequence, crossover design, healthy Chinese male subjects (n = 24) were randomized (1:1:1) to receive a single, oral 8 mg dose of FCN-159 in the fasted state (overnight, > 10 h), and with a low-fat and a high-fat meal, separated by a 10-day washout. PK parameters including time to maximum plasma concentration (C_max) and area under the concentration–time curve (AUC) were compared using geometric least-squares mean ratios (GLSMR), with the fasted state as the reference. A 90% CI for the GLSMR within 80–125% indicated no significant food effect.

Results

A low-fat meal (n = 23) did not affect the PK profile of FCN-159: G LSMR for AUC from time 0 to t (AUC_0–t), 106.9% (90% CI 99.9–114.4%); AUC from time 0 to infinity (AUC_0–∞), 106.8% (90% CI 100.0–114.0%); C_max, 96.4% (90% CI 83.9–110.8%). A high-fat meal (n = 24) did not affect exposure to FCN-159 (GLSMR for AUC_0–t, 99.4%; 90% CI 99.0–106.3%; AUC_0–∞, 99.5 5%; 90% CI 93.2–106.1%), but modestly reduced C_max by 15% (GLSMR 84.9%; 90% CI 74.0–97.3%). Both the low-fat and high-fat meals slightly prolonged the median time to C_max by 0.5 h (90% CI 0.5–1.0 h). FCN-159 was generally well tolerated, with a lower incidence of treatment-emergent adverse events following administration in the fasted state than with a low-fat or high-fat meal (20.8%, 39.1%, and 37.5%, respectively).

Conclusion

Food did not affect the PK profile of FCN-159 to a clinically meaningful extent compared with administration in the fasted state.

Nur mit Berechtigung zugänglich

Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329–41. https://doi.org/10.1158/2159-8290.CD-18-1321.CrossRefPubMedPubMedCentral

Linares MA, Zakaria A, Nizran P. Skin cancer. Prim Care. 2015;42(4):645–59. https://doi.org/10.1016/j.pop.2015.07.006.CrossRefPubMed

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.CrossRefPubMed

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. https://doi.org/10.1038/nature00766.CrossRefPubMed

BioPharma A. Mektovi (binimetinib) US Prescribing Information (January 2019) [June 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210498s001lbl.pdf.

Genentech. Cotelli (cobimetinib) US Prescribing Information (January 2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s002lbl.pdf.

Novartis. Mekinist (trametinib) US Prescribing Information (January 2022) [June 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204114s021lbl.pdf.

Novartis. Mekinist (trametinib) EU Summary of Product Characteristics (May 2022). https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf.

Pierre Fabre Medicament. Mektovi (binimetinib) EU Summary of Product Characteristics (January 2022). [June 2022]. https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf.

10.

Roche. Cotellic (cobimetinib) EU Summary of Product Characteristics (November 2021). https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf.

11.

Galvin R, Watson AL, Largaespada DA, Ratner N, Osum S, Moertel CL. Neurofibromatosis in the era of precision medicine: development of MEK inhibitors and recent successes with selumetinib. Curr Oncol Rep. 2021;23(4):45. https://doi.org/10.1007/s11912-021-01032-y.CrossRefPubMed

12.

Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75–86. https://doi.org/10.1016/B978-0-444-62702-5.00004-4.CrossRefPubMed

13.

AstraZeneca. Kosulego (selumetinib) US Prescribing Information (December 2021) [June 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213756Orig1s003lbl.pdf.

14.

AstraZeneca. Kosulego (selumetinib) EU Summary of Product Characteristics (July 2022) [cited July 2022]. https://www.ema.europa.eu/en/documents/product-information/koselugo-epar-product-information_en.pdf.

15.

Lin S, Zhao X, Zhou Z, Tan H, Chen L, Tan R, et al. Abstract 1951: FCN-159: a novel, potent and selective oral inhibitor of MEK1/2 for the treatment of solid tumors. Cancer Res. 2020;80(16_Suppl):1951. https://doi.org/10.1158/1538-7445.Am2020-1951.CrossRef

16.

Si L, Mao L, Zhou L, Li C, Wang X, Cui C, et al. A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumour activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib). Ann Oncol. 2019;30(Suppl 5):V562.CrossRef

17.

Fosun Pharmaceuticals. Data on File 2022.

18.

Mao L, Guo J, Zhu L, Jiang Y, Yan W, Zhang J, et al. FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS mutations: a phase 1A dose-escalation study. Cancer Res. 2022;82(12 Suppl):1–6403.

19.

Hu X, Zeng K, Xu Z, Li W, Li C, Kang Z, et al. A multicenter, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1. J Clin Oncol. 2022;40(16 Suppl):3011. https://doi.org/10.1200/JCO.2022.40.16_suppl.3011.CrossRef

20.

Cox DS, Papadopoulos K, Fang L, Bauman J, LoRusso P, Tolcher A, et al. Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer. J Clin Pharmacol. 2013;53(9):946–54. https://doi.org/10.1002/jcph.115.CrossRefPubMed

21.

Tomkinson H, McBride E, Martin P, Lisbon E, Dymond AW, Cantarini M, et al. Comparison of the pharmacokinetics of the phase II and phase III capsule formulations of selumetinib and the effects of food on exposure: results from two randomized crossover trials in healthy male subjects. Clin Ther. 2017;39(11):2260−75 e1. https://doi.org/10.1016/j.clinthera.2017.08.022.CrossRefPubMed

22.

Cohen-Rabbie S, Mattinson A, So K, Wang N, Goldwater R. Effect of food on capsule and granule formulations of selumetinib. Clin Transl Sci. 2022;15(4):878–88. https://doi.org/10.1111/cts.13209.CrossRefPubMedPubMedCentral

23.

AstraZeneca. Koselugo^® (selumetinib) US Prescribing Information (December 2021). 2021 [July 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213756Orig1s003lbl.pdf.

24.

Musib L, Choo E, Deng Y, Eppler S, Rooney I, Chan IT, et al. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm. 2013;10(11):4046–54. https://doi.org/10.1021/mp400383x.CrossRefPubMed

25.

Center for Drug Evaluation and Research UFaDA. Assessing the effects of food on drugs in INDs and NDAs—clinical pharmacology considerations guidance for industry (2019).

26.

US Food and Drug Administration. Bioavailability Studies Submitted in NDAs or INDs—General Considerations. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-studies-submitted-ndas-or-inds-general-considerations. Accessed October 2022.

Titel: Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males
verfasst von: Jiangfan Li
Yan Tan
Kexin Li
Ai-Min Hui
Zhuli Wu
Pu Han
Zhen Wei
Jingjun Qiu
Lei Diao
Xuhong Wang
Publikationsdatum: 11.01.2023
Verlag: Springer Healthcare
Erschienen in: Advances in Therapy / Ausgabe 3/2023
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-022-02375-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males